about
Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicityProperties of native brain α-synucleinNative α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2Transcriptional Dynamics at Brain Enhancers: from Functional Specialization to NeurodegenerationLRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesZn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulationPale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of α-synucleinLIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearanceParkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expressionMitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression.Identification of a novel Parkinson's disease locus via stratified genome-wide association studyMitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.Synucleins regulate the kinetics of synaptic vesicle endocytosis.Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons.Resolving the paradox for protein aggregation diseases: NMR structure and dynamics of the membrane-embedded P56S-MSP causing ALS imply a common mechanism for aggregation-prone proteins to attack membranesDevelopment of targeted therapies for Parkinson's disease and related synucleinopathiesThe role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathiesα-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome.Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neuronsGlucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.Evolution of neurodegeneration.Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.Coordination of copper to the membrane-bound form of α-synuclein.GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease.Principles of self-organization in biological pathways: a hypothesis on the autogenous association of alpha-synucleinN-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes.The Identification of Alpha-Synuclein as the First Parkinson Disease Gene.Brain activation of SIRT1: role in neuropathology.Neuropathology of α-synuclein propagation and braak hypothesis.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.α-Synuclein and Parkinsonism: Updates and Future Perspectives.Retrograde Axonal Degeneration in Parkinson Disease.
P2860
Q24337043-C5A6CC61-F24F-4D69-9CA9-CAC15027287FQ26269846-93446868-2AEA-452F-BBEB-394139FF47E0Q26269886-2B5F663A-3F4C-4AFD-91C6-865836B26114Q28067751-6AF201B3-DDCA-4915-8D65-94A52C2A01E6Q28078899-853CEED4-A5C1-421B-9FA6-0EBC9650050EQ28116171-497FDB56-48A2-44F5-BABF-36D1C6E1CCF5Q28585769-354284B2-FAF5-45FC-AEC3-DCD29B3A543AQ28588670-F5C6AE5E-D8EE-4ABA-A2D3-D3E60F9AAE6AQ28598223-EDCBE73D-9CAD-4C97-A34D-92A6361F6F74Q30422362-A3F712D7-772E-4C1D-9D2F-3AA768D77D26Q30571934-E8D92B10-735D-477A-B2E2-B5A44A6C2CFEQ33364885-7B3F7743-F949-4116-8EB7-873A7B93BEC9Q33865356-48B2747A-E4D9-4D72-A80D-4BB74B8195DAQ34095954-CBFC05AE-9116-48A6-AAC2-6C104E60089BQ34211441-0CE3CB2B-EF2A-4197-A0AC-E883439216E7Q34238616-38B07029-60A5-4672-A01E-830BC4EFC4EFQ34305509-574B1532-117D-4D94-B8A2-9F657FE18067Q34450431-4F90061A-2192-46C7-9EAA-7C3267D74A2DQ34503671-C0D905FF-E17E-47B2-B617-E1A8C2D5166BQ34636872-F9DCECE1-1D2F-4E3F-9FF4-242245B18391Q35241298-FB2CC419-A2D7-40DB-883A-67081A8A9D6BQ35863939-6C2DD157-CFEB-4813-A912-527688D86C8CQ35971649-03EA98B3-0FD8-4323-9F81-374DDFA0D835Q36325667-247644B4-173B-4587-B52C-A3EB34FFC87DQ36422521-28FA4C23-DF95-4A9B-A2C1-8DC03D08F06AQ36530499-12001D69-BC30-4598-9D70-46DC794A9040Q36777244-4EBB7E4B-740C-4670-AD59-AC804D12FA64Q36804513-B415EC9D-95AC-4B0E-A819-D7CC784B15B5Q36925651-4EE01083-2250-4135-AF83-6F5C318F84EDQ37115808-B9A6E969-67AF-4532-B35B-6C60F4E1263BQ37528739-44583612-87C6-4DF6-AC0C-57345125CF9CQ37563546-EC063C62-D912-40D1-B764-EE79F24236B5Q37693364-4FD13AB7-0D9D-460E-AE32-43409E72BF98Q38101493-8951B3FC-D599-4441-93BF-70370189F63CQ38580816-60B3DF72-02F8-418E-BCC5-2BA85177185CQ38598375-D7DCAE74-AA92-4CBF-A655-A9FE3DE90843Q38727638-7F047A86-44B6-402D-9C19-DB28A5529999Q38741513-2A7A3900-0A23-46C7-9194-BF1E8BCDC887Q38742153-9FDA5F11-18AB-455C-8EA4-A6DD41CB2A1AQ38785075-F2D7EE9B-DE58-4E7A-8E22-B6A91E119E96
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Parkinson's disease and α-synuclein expression
@ast
Parkinson's disease and α-synuclein expression
@en
type
label
Parkinson's disease and α-synuclein expression
@ast
Parkinson's disease and α-synuclein expression
@en
prefLabel
Parkinson's disease and α-synuclein expression
@ast
Parkinson's disease and α-synuclein expression
@en
P2860
P50
P356
P1433
P1476
Parkinson's disease and α-synuclein expression
@en
P2093
Michael J Devine
P2860
P304
P356
10.1002/MDS.23948
P407
P577
2011-09-01T00:00:00Z